Paying users zone. Data is covered by hidden.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

Allergan PLC (AGN)


Long-term (Investment) Activity Analysis
Quarterly Data

Difficulty: Beginner


Ratios (Summary)

Allergan PLC, long-term (investment) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Net fixed asset turnover hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Net fixed asset turnover (including operating lease, right-of-use asset) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Total asset turnover hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Equity turnover hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05).

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Allergan PLC’s net fixed asset turnover deteriorated from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Allergan PLC’s net fixed asset turnover (including operating lease, right-of-use asset) deteriorated from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Allergan PLC’s total asset turnover improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Allergan PLC’s equity turnover improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.

Net Fixed Asset Turnover

Allergan PLC, net fixed asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net revenues hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Property, plant and equipment, net hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Ratio
Net fixed asset turnover1 hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05).

1 Q2 2019 Calculation
Net fixed asset turnover = (Net revenuesQ2 2019 + Net revenuesQ1 2019 + Net revenuesQ4 2018 + Net revenuesQ3 2018) ÷ Property, plant and equipment, net
= (hidden + hidden + hidden + hidden) ÷ hidden = hidden

2 Click competitor name to see calculations.

Ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Allergan PLC’s net fixed asset turnover deteriorated from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Allergan PLC, net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net revenues hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
 
Property, plant and equipment, net hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Right of use asset, operating leases hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Property, plant and equipment, net (including operating lease, right-of-use asset) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
Biogen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05).

1 Q2 2019 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (Net revenuesQ2 2019 + Net revenuesQ1 2019 + Net revenuesQ4 2018 + Net revenuesQ3 2018) ÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= (hidden + hidden + hidden + hidden) ÷ hidden = hidden

2 Click competitor name to see calculations.

Ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Allergan PLC’s net fixed asset turnover (including operating lease, right-of-use asset) deteriorated from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.

Total Asset Turnover

Allergan PLC, total asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net revenues hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Total assets hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Ratio
Total asset turnover1 hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05).

1 Q2 2019 Calculation
Total asset turnover = (Net revenuesQ2 2019 + Net revenuesQ1 2019 + Net revenuesQ4 2018 + Net revenuesQ3 2018) ÷ Total assets
= (hidden + hidden + hidden + hidden) ÷ hidden = hidden

2 Click competitor name to see calculations.

Ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Allergan PLC’s total asset turnover improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.

Equity Turnover

Allergan PLC, equity turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in thousands)
Net revenues hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Shareholders’ equity hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Ratio
Equity turnover1 hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-15), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05).

1 Q2 2019 Calculation
Equity turnover = (Net revenuesQ2 2019 + Net revenuesQ1 2019 + Net revenuesQ4 2018 + Net revenuesQ3 2018) ÷ Shareholders’ equity
= (hidden + hidden + hidden + hidden) ÷ hidden = hidden

2 Click competitor name to see calculations.

Ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Allergan PLC’s equity turnover improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.